Not provided
Not provided
Not provided
Not provided
PI left site
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study objective is to improve the current and local standard antiseptic treatment by adjusting the antiseptic agent to the antimicrobial resistance testing result, accordingly. Currently, resistance testing will only be performed for the treatment with antibiotics.
Complications like bacterial wound colonization and infections in wound treatment are still a serious problem. Several therapy approaches are available to treat these complications, e.g. surgical wound debridement, antimicrobial therapy that can be divided into a local and a systemic antisepsis.
The local antisepsis (the local utilization of antiseptics directly to the wound) is in many ways advantageous to the systemic antisepsis (orally or intravenously administered antibiotics): e. g. the direct contact of the antiseptic to the bacteria at the site of infection whereas antibiotics may not sufficiently reach the wound due to limited blood perfusion of wounds; growing utilization of systemic antisepsis also leads to an increasing number of resistant bacteria worldwide. To the concerns of many specialists, the first pan-resistant bacterial strain which is resistant to all available antibiotics including colistin was recently published.
In future, the role of local antisepsis therefore becomes more important in the antimicrobial treatment. Luckily, resistances of local antiseptics occur slowly due to the chemical and structural characteristics of antiseptics but even resistances of bacteria to antiseptics were reported. Unlike the antimicrobial resistance testing for antibiotics that is done in the clinical routine, such testing is not a standard procedure for antiseptics for no obvious reason. The utilization of antiseptics is determined by the availability of products provided within the institution and preferences of the clinician. Thus, it is unknown whether the chosen antiseptic has any bactericidal effect on the confirmed bacteria.
University Hospital RWTH Aachen Wound Care only uses polyhexanide and octenisept. Iodine-containing preparations are explicitly not desired.Improvement (bacteria reduction, acceleration of wound healing) of the local antiseptic therapy by adapting the antiseptic to the results of antimicrobial resistance testing. Antimicrobial resistance testing has so far only been used to adapt systemic antibiotic therapy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard Care | No Intervention | Octenisept will be used as standard care antiseptic for dressing change | |
| Resistance testing | Experimental | Patients will be first tested on resistance to Octenisept and Serasept and will receive the appropriate antiseptic after reviewing the results |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Octenisept and Serasept | Drug | Swab probes of wounds will be taken upon study inclusion and analysed for resistance on Octenisept and Serasept. If the patient indicates resistance on one of the antiseptics, he/she will receive the other antiseptic for wound dressings |
| Measure | Description | Time Frame |
|---|---|---|
| Change in bacteria rate | determination of the relative proportion of isolates to the total flora in the wound | up to 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of wound related adverse events | review of medical charts | up to 12 months |
| Change in Pressure Ulcers: Scale for Healing (PUSH) score | score 0-17; 17=big and severe wound |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Christian Stoppe, Prof. | Aachen University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital RWTH Aachen | Aachen | North Rhine-Westphalia | 52074 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003668 | Pressure Ulcer |
| ID | Term |
|---|---|
| D012883 | Skin Ulcer |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000718682 | octenidine and phenoxyethanol drug combination |
Not provided
Not provided
Not provided
This is monocentric, prospective, controlled, open, randomized, 2-armed interventional pilot trial.
Not provided
Not provided
Not provided
Not provided
| up to 12 months |
| Change in Bates-Jensen Score | Score 13-65; 13-20=minimal severity class; 41-65 extreme severity class | up to 12 months |
| Laboratory Parameters - Change in C-reactive protein (CRP) | mg/L | up to 12 months |
| Laboratory Parameters - Change in Leukocytes | 10⁹/L or /nL | up to 12 months |
| Laboratory Parameters - Change in hemoglobin | g/dl | up to 12 months |
| Laboratory Parameters - Change in hematokrit | up to 12 months |
| Laboratory Parameters - Change in creatinine | µmol/L or mg/dl | up to 12 months |
| Laboratory Parameters - Change in glomerular filtration rate (GFR) | ml/min/1,73m^2 | up to 12 months |
| Laboratory Parameters - Change in Uric acid | mg/dl | up to 12 months |
| Laboratory Parameters - Change in glutamic-pyruvic transaminase (GPT) | IU/L | up to 12 months |
| Laboratory Parameters - Change in Glutamat-Oxalacetat- Transaminase (GOT) | IU/L | up to 12 months |
| Laboratory Parameters - Change in Glucose | mmil/L or mg/dl | up to 12 months |
| Hospital length of stay | from study inclusion until hospital discharge | up to 12 months |
| Rate of antibiotics used | chart review | up to 12 months |
| Length of bed confinement | chart review | up to 12 months |